دورية أكاديمية

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

التفاصيل البيبلوغرافية
العنوان: Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial
المؤلفون: Bethune, Claire, Boffito, Marta, Bula, Marcin, Burns, Fiona M, Clark, Rebecca, Dasyam, Dileep, Drysdale, Simon, Faust, Saul, Gkrania-Klotsas, Effrossyni, Green, Christopher, Hassanin, Hana, Heath, Paul, Heer, Amardeep, Helliwell, Toby, Hormis, Anil, Kalra, Philip, Lazarus, Rajeka, Moran, Ed, Ndikum, John, Page, Iain, Price, David, Probert, Nick, Ramjee, Mahadev, Rampling, Tommy, Randeva, Harpal S, Ryder, Stephen, Steer, John, Thompson, Emma, Torku, David, Querton, Benedicte, Corbic Ramljak, Irena, Dewasthaly, Shailesh, Jaramillo, Juan Carlos, Dubischar, Katrin, Krammer, Michael, Weisova, Petronela, Hochreiter, Romana, Eder-Lingelbach, Susanne, Taucher, Christian *, *, Finn, Adam
المصدر: In The Lancet Infectious Diseases December 2022 22(12):1716-1727
قاعدة البيانات: ScienceDirect
الوصف
تدمد:14733099
DOI:10.1016/S1473-3099(22)00502-3